Prenatal and Newborn Genetic Testing Market Report 2026

The prenatal and newborn genetic testing market size has grown rapidly in recent years. It will grow from $7.6 billion in 2025 to $8.51 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to increasing awareness of genetic disorders, expansion of maternal and neonatal healthcare services, rising institutional screening programs, availability of diagnostic laboratories, improvements in genetic testing accuracy.

The prenatal and newborn genetic testing market size is expected to see rapid growth in the next few years. It will grow to $13.65 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine approaches, rising demand for early-stage disease detection, expansion of newborn screening mandates, growing investments in genomics infrastructure, increasing use of digital health platforms. Major trends in the forecast period include increasing adoption of non-invasive prenatal testing, rising use of advanced genetic screening panels, growing integration of ai in genetic risk analysis, expansion of high-throughput sequencing platforms, enhanced focus on early detection of congenital disorders.

The increasing incidence of genetic disorders is expected to drive the growth of the prenatal and newborn genetic testing market in the coming years. Genetic disorders are medical conditions caused by abnormalities or mutations in an individual’s DNA or genetic material. Prenatal and newborn genetic testing enables the early detection of such disorders, often before clinical symptoms appear, allowing healthcare providers to implement timely interventions and appropriate treatment strategies. For instance, in May 2024, according to the Centers for Disease Control and Prevention, a US-based public health agency, sickle cell disease affects approximately 100,000 individuals in the United States, with more than 90% of cases occurring among non-Hispanic Black or African American populations and an estimated 3% to 9% among Hispanic or Latino populations. Therefore, the rising prevalence of genetic disorders is contributing to the growth of the prenatal and newborn genetic testing market.

Major companies operating in the prenatal and newborn genetic testing market are focusing on the development of innovative screening solutions, such as noninvasive prenatal screening tests, to improve accessibility and affordability while delivering reliable diagnostic services. Noninvasive prenatal screening, also known as noninvasive prenatal testing, is an advanced and safe genetic screening approach used during pregnancy to evaluate the risk of specific fetal chromosomal abnormalities. For instance, in January 2024, Natera, Inc., a US-based genetic testing company, introduced a fetal RhD noninvasive prenatal test designed to determine fetal RhD status and support obstetric care during nationwide shortages of Rho(D) immune globulin. This test is supported by a large clinical validation study involving more than 650 RhD-negative patients with confirmed outcomes, demonstrating 100% sensitivity and greater than 99% specificity. Natera’s test can be administered early in pregnancy, enabling timely clinical decision-making and improved patient management.

In February 2024, CooperSurgical Inc., a US-based medical equipment manufacturing company, entered into a partnership with Fulgent Genetics. Through this collaboration, CooperSurgical seeks to expand its service offerings by integrating Fulgent Genetics’ expertise in advanced genetic testing for families utilizing the Cord Blood Registry. Fulgent Genetics Inc. is a US-based company that provides prenatal and newborn genetic testing services.

Major companies operating in the prenatal and newborn genetic testing market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostic Incorporated, Agilent Technologies Inc, Illumina Inc, PerkinElmer Genomics, Quidel Corporation, Bio Rad Laboratories Inc, Qiagen NV, Werfen SA, DiaSorin SpA, BGI Group, Natera Inc, Trinity Biotech plc, Meridian Bioscience Inc, Sekisui Diagnostics, Ariosa Diagnostics Inc, AccuBioTech Co Ltd, Sequenom Inc, Roche Diagnostics International AG.

North America was the largest region in the prenatal and newborn genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prenatal and newborn genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prenatal and newborn genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the prenatal and newborn genetic testing market by increasing costs of imported reagents, sequencing instruments, PCR systems, and microarray components used across screening and diagnostic workflows. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported high-precision laboratory equipment, while Asia-Pacific faces higher consumable and instrumentation costs. These tariffs are elevating testing prices and slowing laboratory expansion plans. However, they are also encouraging domestic production of testing kits, regional reagent manufacturing, and localized assembly of diagnostic instruments, supporting long-term supply chain stability.

The prenatal and newborn genetic testing market research report is one of a series of new reports that provides prenatal and newborn genetic testing market statistics, including prenatal and newborn genetic testing industry global market size, regional shares, competitors with a prenatal and newborn genetic testing market share, detailed prenatal and newborn genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal and newborn genetic testing industry. This prenatal and newborn genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prenatal and newborn genetic testing involves medical procedures and screening methods carried out during pregnancy and after birth to evaluate the genetic health and potential risk factors of both the developing fetus and the newborn. These tests are used to identify genetic disorders, congenital abnormalities, or inherited conditions that could impact a child’s health or development.

The primary product categories in prenatal and newborn genetic testing include consumables and instruments. Instruments are specialized devices designed to perform specific testing and measurement functions, including various genetic analyzers used by healthcare professionals to conduct screenings and diagnostic tests. The different screening methods include non-invasive prenatal testing, chorionic villus sampling, amniocentesis, maternal serum screening, and others. The conditions assessed include Down syndrome, phenylketonuria, cystic fibrosis, and sickle cell anemia. These tests are utilized by end users such as hospitals, maternity and specialty clinics, and diagnostic centers.

The prenatal and newborn genetic testing market consists of revenues earned by entities by providing services such as prenatal screening tests, prenatal diagnostic tests, carrier screening for genetic conditions, and newborn screening tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The prenatal and newborn genetic testing market also includes sales of electrophoresis equipment, genetic sequencing machines, and microarray analysis instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.